Search results

This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

Result type

NICE guideline

Published

6 July 2016

Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

5 June 2019

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 May 2016

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Last updated

23 November 2016

Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

27 March 2019

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 June 2014

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Result type

Evidence summary

Published

3 July 2015

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Result type

Evidence summary

Published

10 September 2013

This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

Result type

NICE guideline

Last updated

29 June 2022

Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 October 2023

advanced stages of liver disease. Pharmacological treatment (for example, pioglitazone or vitamin E) could prevent progression to...

Result type

Research recommendation

Published

24 August 2016

This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

Result type

Technology appraisal guidance

Published

27 March 2001

In development [GID-TA11104] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease

Result type

Diagnostics guidance

Published

12 January 2023